Thymoquinone and aerobic exercise mitigate HFpEF-induced cardiac injury via Apaf1/Cycs axis regulation

TL;DR

Thymoquinone and aerobic exercise together protect the heart in a type of heart failure by reducing cell death and stress.

Contribution

The study reveals a synergistic effect of thymoquinone and exercise in mitigating HFpEF through the Apaf1/Cycs apoptotic pathway.

Findings

Combined TQ and aerobic exercise reduced myocardial fibrosis, apoptosis, and oxidative stress in HFpEF.

The treatment downregulated the interaction between Apaf1 and Cycs, suppressing cardiomyocyte apoptosis.

The combination showed better results than either intervention alone in an HFpEF model.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a prevalent clinical syndrome associated with high morbidity and mortality. Oxidative stress, apoptosis, and fibrosis are central to its pathophysiology. This study aimed to investigate the synergistic cardioprotective effects of thymoquinone (TQ) and aerobic exercise, with a particular focus on the Apaf1/Cycs-mediated apoptotic pathway.

Male C57BL/6J mice were randomly assigned to five groups: Control, HFpEF, HFpEF + TQ, HFpEF + exercise, and HFpEF + TQ + exercise. HFpEF was induced by a high-fat diet combined with Nω-Nitro-L-arginine methyl ester (L-NAME) administration for 10 weeks. TQ (50 mg/kg/day) and aerobic exercise (60% of maximal velocity, 5 days/week for 12 weeks) were applied as interventions. In vitro HFpEF models were established in H9c2 cardiomyoblast cells treated with L-NAME. Histological and molecular changes were assessed by immunofluorescence, co-immunoprecipitation, and TUNEL assays.

The combined treatment of TQ and aerobic exercise significantly reduced myocardial fibrosis, apoptosis, and oxidative stress compared with either intervention alone. Mechanistically, the combination downregulated the interaction between Apaf1 and Cycs, thereby suppressing cardiomyocyte apoptosis.

These findings demonstrate that TQ and aerobic exercise exert synergistic cardioprotective effects in HFpEF by attenuating oxidative stress, fibrosis, and apoptosis through inhibition of the Apaf1/Cycs apoptotic pathway. The results provide new insights into adjunctive therapeutic strategies for HFpEF management.

Figures